Dupixent Lawsuit in Indiana - Free Case Review

Free Case Review

Start Your Free Review

Answer 2-3 quick questions to review your potential case.

Key Takeaway

Indiana's large population of 6.8 million and extensive healthcare infrastructure drive substantial Dupixent prescribing, with an estimated 52,000 patients since 2017. Indianapolis serves as the pharmaceutical hub, with Indiana University Health, IU Simon Comprehensive Cancer Center, and a large community of specialty dermatologists and allergists. Eli Lilly's headquarters in Indianapolis have made the state a pharmaceutical industry center, though Lilly's presence does not directly benefit Sanofi or Regeneron in litigation. Indiana's Product Liability Act (Ind. Code § 34-20-1-1 et seq.) governs pharmaceutical claims and includes a potentially significant 10-year statute of repose that could bar claims for patients whose Dupixent use began more than 10 years before filing. The Southern District of Indiana in Indianapolis has managed pharmaceutical cases competently, and Indiana's Midwestern jury pools tend to be pragmatic in evaluating corporate conduct.

Written By

People's Justice Legal Research Team

Statute of Limitations

Indiana: 2 years for product liability (Ind. Code § 34-11-2-4). Discovery rule applies — the limitations period begins when the plaintiff knew or should have known of the injury. Indiana also imposes a 10-year product liability statute of repose (Ind. Code § 34-20-3-1).

2 years from discovery of injury (10-year repose)

Filing Venue

Where to File in Indiana

Indiana has two federal judicial districts: the Northern District (Hammond/Fort Wayne/South Bend) and Southern District (Indianapolis/Evansville). The Southern District handles most pharmaceutical litigation filed in Indianapolis. Indiana follows a modified comparative fault system (51 percent bar) and has a Product Liability Act that governs claims against drug manufacturers. The state caps punitive damages at the greater of $50,000 or three times compensatory damages.

Indiana Data

Exposure in Indiana

Source: IQVIA prescription data estimates

Source: IU Simon Cancer Center / NCI

Source: Ind. Code § 34-20-3-1

FAQ

Frequently Asked Questions

See details below.

Back to Dupixent Lawsuit Lawsuit Overview